tedatioxetine
Tedatioxetine is an experimental antidepressant developed by H. Lundbeck A/S for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). It acts as a triple reuptake inhibitor (TRI) with preference for serotonin and norepinephrine over dopamine, and as an antagonist at 5-HT2A, 5-HT2C, 5-HT3, and α1A-adrenergic receptors. In 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Oct 1, 2007 (NCT00599911)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 3 (5-HT3) receptorANTAGONIST
Serotonin 3 (5-HT3) receptor antagonist
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
- Serotonin 2c (5-HT2c) receptorANTAGONIST
HTR2C antagonist
- Serotonin transporterINHIBITOR
SLC6A4 inhibitor
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
- Dopamine transporterINHIBITOR
SLC6A3 inhibitor
- Alpha-1a adrenergic receptorANTAGONIST
ADRA1A antagonist
Chemistry & pharmacology
SMILES
Cc1ccc(Sc2ccccc2C2CCNCC2)cc1- Mol. weight
- 283.44 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaTedatioxetine ↗
- ChEMBLCHEMBL2104986 ↗
Also known as
- lu aa24530
- lu aa24530
- lu-aa24530
- lu-aa24530
- tedatioxetine
- tedatioxetine
- tedatioxetine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00599911 | Phase 2 | Oct 1, 2007 | Lundbeck |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Lundbeck | For profit | 1 | 1 | 1 | 2007 |